For Healthcare Professionals

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)


About the study

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

Participant has documented diagnosis of MM and measurable disease, defined as any of the following:

  1. M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or
  2. M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP)
  3. For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
  4. Participants received 1 to 3 prior lines of antimyeloma therapy.
  5. Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.


Exclusion Criteria:

Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:

a. Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks or less are not excluded.

  1. For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
  2. Participant has had prior treatment with mezigdomide or pomalidomide.

Other protocol-defined criteria apply.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Relapsed or Refractory Multiple Myeloma

Age (in years)



Phase 3

Participants needed


Est. Completion Date

Nov 30, 2033

Treatment type



Celgene identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.